IGF1R and familial pancreatic carcinoma: Clinical trials, exemplified by the phase III trial investigating ganitumab, an antibody targeting IGF1R in conjunction with gemcitabine for metastatic pancreatic cancer patients, failed to yield a statistically significant improvement in survival (115).